Anna Biró1, Ulrich Stephani2, Tiziana Tarallo2, Thomas Bast3, Kurt Schlachter4, Martin Fleger4, Gerhard Kurlemann5, Barbara Fiedler5, Steffen Leiz6, Marina Nikanorova7, Markus Wolff8, Arnd Müller1, Christina Selch1, Martin Staudt1, Gerhard Kluger1. 1. Department of Pediatric Neurology and Neurological Rehabilitation, Schön Klinik Vogtareuth, Vogtareuth, Germany. 2. Department of Neuropediatrics, Christian-Albrechts University, University Medical Center Schleswig-Holstein, Kiel, Germany. 3. Epilepsy Center Kork, Kehl, Germany. 4. Department of Pediatrics, Bregenz Regional Hospital, Bregenz, Austria. 5. Department of Neuropediatrics, University Children's Hospital Münster, Münster, Germany. 6. Department of Pediatrics, Dritter Orden Clinic, München, Germany. 7. Children's Department, Danish Epilepsy Centre, Dianalund, Denmark. 8. Department of Pediatric Neurology, University Children's Hospital Tübingen, Tübingen, Germany.
Abstract
OBJECTIVE: This article aims to report the first clinical experiences concerning effectiveness and tolerability of perampanel (PER) in a pediatric population with refractory epilepsies. PATIENTS AND METHODS: This nonsponsored, observational, retrospective survey was conducted through collaboration with multiple centers in Europe. The clinical course of the first pediatric patients treated in these centers with PER was documented with the help of a questionnaire completed by the treating physicians. Effectiveness and adverse effects were evaluated. The study population consisted of 58 patients (mean age, 10.5 years; range, 2-17 years), suffering from various refractory epilepsies, classified as focal epilepsy (n = 36), unclassified generalized epilepsy (n = 12), Lennox-Gastaut syndrome (n = 5), West syndrome (n = 3), and Dravet syndrome (n = 2). RESULTS: The response rate (≥ 50% seizure reduction) after the first 3 months of therapy was 31% (18/58 patients) in total. Complete seizure control was achieved in five patients (9% overall). Aggravation of seizures occurred in five cases (9%). The most frequently occurring adverse effects were reduced vigilance or fatigue (n = 16) and behavioral changes (n = 14). DISCUSSION: PER seems to be effective also in children and adolescents with pharmaco-refractory epilepsies. Tolerability was acceptable. Georg Thieme Verlag KG Stuttgart · New York.
OBJECTIVE: This article aims to report the first clinical experiences concerning effectiveness and tolerability of perampanel (PER) in a pediatric population with refractory epilepsies. PATIENTS AND METHODS: This nonsponsored, observational, retrospective survey was conducted through collaboration with multiple centers in Europe. The clinical course of the first pediatric patients treated in these centers with PER was documented with the help of a questionnaire completed by the treating physicians. Effectiveness and adverse effects were evaluated. The study population consisted of 58 patients (mean age, 10.5 years; range, 2-17 years), suffering from various refractory epilepsies, classified as focal epilepsy (n = 36), unclassified generalized epilepsy (n = 12), Lennox-Gastaut syndrome (n = 5), West syndrome (n = 3), and Dravet syndrome (n = 2). RESULTS: The response rate (≥ 50% seizure reduction) after the first 3 months of therapy was 31% (18/58 patients) in total. Complete seizure control was achieved in five patients (9% overall). Aggravation of seizures occurred in five cases (9%). The most frequently occurring adverse effects were reduced vigilance or fatigue (n = 16) and behavioral changes (n = 14). DISCUSSION: PER seems to be effective also in children and adolescents with pharmaco-refractory epilepsies. Tolerability was acceptable. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Martin J Brodie; Frank Besag; Alan B Ettinger; Marco Mula; Gabriella Gobbi; Stefano Comai; Albert P Aldenkamp; Bernhard J Steinhoff Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468